Neoadjuvant Trastuzumab Concurrent with Nonanthracycline-based Regimens for HER2-positive Locally Advanced Breast Cancer

Neoadjuvant Trastuzumab Concurrent with Nonanthracycline-based Regimens for HER2-positive Locally Advanced Breast Cancer

Trastuzumab, a humanized monoclonal antibody directed against the external domain of the HER-2 protein, has shown remarkable activity against HER-2 positive breast cancer. Consequently, the use of adjuvant trastuzumab plus chemotherapy in patients with HER2-positive stage breast cancer (stage I to I...

Full description

Bibliographic Details
Main Authors: Wei-Hsin Liu, Mei-Ching Liu, Ben-Long Yu, Skye Hung-Chun Cheng, Ming-Yuan Li, Chi-Feng Chung, Tzung-De Wang, Chi-Feng Hung
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2014-09-01
Series:Journal of Cancer Research and Practice
Subjects:
trastuzumab
locally advanced breast cancer
neoadjuvant therapy
pathologic complete response (pCR)
Online Access:http://www.sciencedirect.com/science/article/pii/S2311300616300416

Internet

http://www.sciencedirect.com/science/article/pii/S2311300616300416

Similar Items